Antidepresivos, dolor y cáncer

Psicooncología, 2006
Source: OAI

ABSTRACT Existe una relación entre estrés, depresión y dolor, relación que es más evidente en los pacientes oncológicos. Teniendo en cuenta la eficacia de los antidepresivos en el tratamiento de ciertos tipos de dolor crónico y la elevada prevalencia de cuadros depresivos en pacientes oncológicos, consideramos interesante revisar las características del dolor crónico, especial¬mente en estos pacientes, y la relación entre dolor, cáncer y depresión. Por otra parte, la depresión y dolor tienen unas vías comunes que explicarían el mecanismo analgésico de los antidepresivos. Sin embargo, en clínica, la acción antidepresiva y la analgésica son total¬mente independientes. En el dolor crónico los antidepresivos más eficaces son los tricíclicos, pero debido a sus efectos indeseables se está tendiendo al uso de los nuevos antidepresivos duales como la venlafaxina y duloxetina. There is a close relationship between stress, depression, and pain, especially in cancer pa¬tients. As the efficacy of antidepressants in some types of chronic pain is well documented and the prevalence of depression is very high in cancer patients, we will review the main features of chronic pain, chronic pain in can¬cer, and the relationship between pain, can¬cer, and depression. Depression and pain have common pathways mediating the therapeutic effects of most currently available antidepres¬sants. Clinically, the effect of antidepressants on pain and on affective symptoms is indepen¬dent. In terms of efficacy, tricyclic antidepres¬sants tend to work better but their side effect profile favor the use of the new dual reuptake inhibitors as venlafaxine or duloxetine.

Download full-text


Available from: Juan Gibert-Rahola, Dec 29, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinically relevant pain states are usually characterized as either inflammatory or neuropathic. While inflammatory pain results from tissue injury or damage, neuropathic pain results from damage or disease of nerve fibers. In either pain state, both the peripheral and the central nociceptive system contribute significantly to the generation of pain. During inflammation peripheral nociceptors ("pain fibers") are sensitized (peripheral sensitization), and upon nerve injury or nerve disease peripheral nerve fibers develop ectopic discharges originating from the site of the nerve lesion or the cell body of damaged fibers. As a consequence a complex neuronal response is evoked in the spinal cord where neurons become hyperexcitable (central sensitization).Central sensitization is a neuronal process that amplifies the activity from the periphery. Numerous molecular mechanisms are involved in peripheral and central nociceptive processes including rapid functional changes of signaling (increase of excitability) and long-term regulatory changes such as upregulation of mediator/receptor systems. The conscious pain is generated by thalamocortical networks that produce both sensory discriminative and affective components of the pain response.
    Der Orthopäde 02/2007; 36(1):8, 10-2, 14-6. · 0.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peripheral neuropathic pain, that clinical pain syndrome associated with lesions to the peripheral nervous system, is characterized by positive and negative symptoms. Positive symptoms include spontaneous pain, paresthesia and dysthesia, as well as a pain evoked by normally innocuous stimuli (allodynia) and an exaggerated or prolonged pain to noxious stimuli (hyperalgesia/hyperpathia). The negative symptoms essentially reflect loss of sensation due to axon/neuron loss, the positive symptoms reflect abnormal excitability of the nervous system. Diverse disease conditions can result in neuropathic pain but the disease diagnosis by itself is not helpful in selecting the optimal pain therapy. Identification of the neurobiological mechanisms responsible for neuropathic pain is leading to a mechanism-based approach to this condition, which offers the possibility of greater diagnostic sensitivity and a more rational basis for therapy. We are beginning to move from an empirical symptom control approach to the treatment of pain to one targeting the specific mechanisms responsible. This review highlights some of the mechanisms underlying neuropathic pain and the novel targets they reveal for future putative analgesics.
    Life Sciences 05/2004; 74(21):2605-10. DOI:10.1016/j.lfs.2004.01.003 · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There have been considerable advances in our understanding of the pathophysiology of neuropathic pain. There is still a lack of consensus about the optimal therapeutic strategy of such conditions, however. Drugs are generally selected on the basis of their established efficacy in randomized controlled studies in etiologically based groups of patients. These studies have been important in confirming the efficacy of antidepressants, antiepileptics, local anesthetics and derivatives, capsaicin, opioids, and N-methyl-D-aspartate antagonists in neuropathic pain, specifically painful diabetic neuropathy and postherpetic neuralgia. More specific therapeutic strategies based on precise quantified assessment of the various components of neuropathic pain are now increasingly used and may provide insight regarding the effects of treatments of particular symptoms (e.g., allodynia, hyperalgesia). In some cases, such assessment may also help to analyze the mechanisms involved in pain, thus allowing selection of treatment on a more rational basis. A mechanism-based approach seems promising for clinical research studies, although its application in current management remains challenging.
    Clinical Journal of Pain 10/2000; 16(3 Suppl):S118-30. DOI:10.1097/00002508-200009001-00003 · 2.70 Impact Factor
Show more